|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls.
|
31414945 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Paradoxical Role of Glypican-1 in Prostate Cancer Cell and Tumor Growth.
|
31391540 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This approach is clinically relevant as a companion test to the already available diagnostic tools, since patients with GPC1-positive exosomes in peripheral blood showed decreased tumor free survival.
|
31400579 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proportion of cases by tumor type showing staining with glypican-1 and the H-score for each tumor type were evaluated.
|
29785020 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, GPC1 levels were enriched in PDAC crExos (<i>n</i> = 11), compared to the source tumors (<i>n</i> = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; <i>P</i> < 0.001).
|
29721179 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
On immunohistochemical staining, high expression levels of GPC1 were detected in about 50% of uterine cervical cancer tissues and also in a tumor that had relapsed after chemoradiotherapy.
|
29055044 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-GPC1 mAb also inhibited tumor growth of GPC1 positive ESCC patients derived tumor xenograft models.
|
28445969 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of glypican-1 is differentially altered among different types of malignancies, suggesting a possible role in the tumorigenesis and biological behavior of these neoplasms.
|
25046223 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Remarkably, the enhanced expression of Notum, a conserved feedback antagonist of Wnt, was observed in tumors along with alterations in Glypican-1 and Glypican-3 levels.
|
26517809 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Changes in proteoglycan core proteins differ depending on their location; those located intracellularly or in the extracellular matrix show very similar alteration patterns, while those located on the cell surface vary greatly depending on the nature of the tumor: glypicans 1, 3, 6 and betaglycan are affected in the non-metastatic tumors, whereas in the metastatic, only glypican-1 and syndecan-1 are modified, the latter showing opposing alterations in levels of RNA and of protein, suggesting post-transcriptional regulation in these tumors.
|
26482785 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Levels of GPC1(+) crExos correlate with tumour burden and the survival of pre- and post-surgical patients.
|
26106858 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GPC1 expression leads to a significant downregulation of the tumor suppressors pRb, Cip/Kip cyclin-dependent kinase inhibitors (CKIs), and CDH1, and upregulation of the pro-oncogenic proteins cyclin E, cyclin-dependent kinase 2 (CDK2), Skp2, and Cdt1.
|
24019070 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a good correlation between glypican-1 and syndecan-1 expression in the tumors.
|
11454708 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, glypican-1 antisense-expressing PANC-1 cells exhibited a significantly reduced ability to form tumors in nude mice in comparison with parental and sham-transfected PANC-1 cells.
|
10505759 |
1999 |